Decompensated Cirrhosis May Be Another HCV Edge For Gilead; Bristol, J&J Still In Contention
Executive Summary
Bristol and Johnson & Johnson have not abandoned their efforts to take a relevant place in the HCV market, although J&J isn't expected to produce triple combination data until next year.